Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn Hwa Young | - |
dc.contributor.author | 이가희 | - |
dc.date.accessioned | 2024-01-25T05:31:18Z | - |
dc.date.available | 2024-01-25T05:31:18Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.issn | 2093-5978 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/71531 | - |
dc.description.abstract | Thyroid hormone plays a critical role in fetal growth and development, and thyroid dysfunction during pregnancy is associated with several adverse outcomes, such as miscarriage and preterm birth. In this review, we introduce and explain three major changes in the revised Korean Thyroid Association (KTA) guidelines for the diagnosis and management of thyroid disease during pregnancy: first, the normal range of thyroid-stimulating hormone (TSH) during pregnancy; second, the treatment of subclinical hypothyroidism; and third, the management of euthyroid pregnant women with positive thyroid autoantibodies. The revised KTA guidelines adopt 4.0 mIU/L as the upper limit of TSH in the first trimester. A TSH level between 4.0 and 10.0 mIU/L, combined with free thyroxine (T4) within the normal range, is defined as subclinical hypothyroidism, and a TSH level over 10 mIU/L is defined as overt hypothyroidism regardless of the free T4 level. Levothyroxine treatment is recommended when the TSH level is higher than 4 mIU/L in subclinical hypothyroidism, regardless of thyroid peroxidase antibody positivity. However, thyroid hormone therapy to prevent miscarriage is not recommended in thyroid autoantibody-positive women with normal thyroid function. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한내분비학회 | - |
dc.title | Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines | - |
dc.title.alternative | Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines | - |
dc.type | Article | - |
dc.identifier.doi | 10.3803/EnM.2023.1696 | - |
dc.identifier.bibliographicCitation | Endocrinology and Metabolism, v.38, no.3, pp 289 - 294 | - |
dc.identifier.kciid | ART002968734 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001033628700001 | - |
dc.identifier.scopusid | 2-s2.0-85168622173 | - |
dc.citation.endPage | 294 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 289 | - |
dc.citation.title | Endocrinology and Metabolism | - |
dc.citation.volume | 38 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Pregnancy | - |
dc.subject.keywordAuthor | Hypothyroidism | - |
dc.subject.keywordAuthor | Anti-thyroid autoantibodies | - |
dc.subject.keywordPlus | SUBCLINICAL HYPOTHYROIDISM | - |
dc.subject.keywordPlus | LEVOTHYROXINE TREATMENT | - |
dc.subject.keywordPlus | REFERENCE INTERVALS | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordPlus | TRIMESTER | - |
dc.subject.keywordPlus | AUTOIMMUNITY | - |
dc.subject.keywordPlus | MISCARRIAGE | - |
dc.subject.keywordPlus | DEFICIENCY | - |
dc.subject.keywordPlus | HORMONES | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.